After specifically filtering the datasets for the frequency of tumor metastasis, survival or recurrence, we observed significant positive correlations between enhanced SERPINB2 levels and higher overall metastasis/recurrence rates as well as a lower 5-year survival in breast (nonaggressive: 297 patients and aggressive: 205 patients), colorectal (non-relapse: 176 patients and relapse: 50 patients) and liver (noninvasive: 93 patients and invasive: 16 patients) cancers (Figure 5A–C). This evidence concerns the gene SERPINB2 and cancer.